Related Experiment Video
Updated: Jun 6, 2026

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
Published on: February 10, 2023
[Screening for thrombophilic abnormalities in very elderly patients]
Hélène Anard-Michelot1, Virginie Siguret, Isabelle Gouin-Thibault
1Service de médecine, Faculté des sciences pharmaceutiques et biologiques, Université Paris Descartes.
Few data are available regarding biological risk factors for venous thromboembolism in the elderly who are at high risk of thrombosis. In the present study, we assessed the prevalence of antithrombin, protein C, protein S deficiency, G1691A factor V Leiden and G20210A prothrombin (FII) gene variant, and antiphospholipid antibodies in patients over 75 years who were referred to us for thrombophilia testing and who presented with unprovoked recurrent venous thromboembolic disease or venous thrombosis at unusual site. Seventy-eight patients, mean aged 86 years, were included in the cohort. No deficiency in natural coagulation inhibitors was found. Ten patients (12.8%) and 6 patients (7.7%) were found heterozygous carriers of the factor V Leiden and of the G20210A FII mutation, respectively. One patient was a double heterozygote. Two patients were diagnosed with antiphospholipid syndrome. These results are discussed along with those obtained in cohorts of elderly patients or in cohorts of younger patients presenting with idiopathic venous thromboembolic disease, either recurrent or not. Our results trend to confirm the recently published French recommendations regarding inherited thrombophilia screening in the elderly: in patients aged 60 years or older, testing should be limited given the weak impact of this finding on the anticoagulation management.
Few data are available regarding biological risk factors for venous thromboembolism in the elderly who are at high risk of thrombosis. In the present study, we assessed the prevalence of antithrombin, protein C, protein S deficiency, G1691A factor V Leiden and G20210A prothrombin (FII) gene variant, and antiphospholipid antibodies in patients over 75 years who were referred to us for thrombophilia testing and who presented with unprovoked recurrent venous thromboembolic disease or venous thrombosis at unusual site. Seventy-eight patients, mean aged 86 years, were included in the cohort. No deficiency in natural coagulation inhibitors was found. Ten patients (12.8%) and 6 patients (7.7%) were found heterozygous carriers of the factor V Leiden and of the G20210A FII mutation, respectively. One patient was a double heterozygote. Two patients were diagnosed with antiphospholipid syndrome. These results are discussed along with those obtained in cohorts of elderly patients or in cohorts of younger patients presenting with idiopathic venous thromboembolic disease, either recurrent or not. Our results trend to confirm the recently published French recommendations regarding inherited thrombophilia screening in the elderly: in patients aged 60 years or older, testing should be limited given the weak impact of this finding on the anticoagulation management.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Drug Dosing: Geriatric Patients
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Pharmacodynamics in Geriatric Patients: Effects of Age